UK markets open in 5 hours 16 minutes

QIAGEN N.V. (QGEN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
51.52-1.12 (-2.13%)
At close: 4:00PM EDT
51.52 0.00 (0.00%)
After hours: 05:38PM EDT

QIAGEN N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
http://www.qiagen.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees5,900

Key executives

NameTitlePayExercisedYear born
Mr. Thierry BernardCEO, MD & Member of Management Board2.41MN/A1965
Dr. Roland SackersCFO, MD & Member of Management Board977.5kN/A1969
Dr. Barthold PieningSr. VP & Head of Global OperationsN/AN/A1958
Mr. John GilardiVP of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Stephany FosterSr. VP & Head of HRN/AN/AN/A
Dr. Thomas SchweinsSr. VP of Life Science Bus. AreaN/AN/AN/A
Dr. Thomas TheuringerSr. Director & Head of External CommunicationsN/AN/AN/A
Mr. Jean-Pascal ViolaSr. VP, Head of Molecular Diagnostics Bus. Area & Corp. Bus. Devel.N/AN/AN/A
Dr. Jonathan G. Sheldon Ph.D.Sr. VP of Qiagen Digital Insights Bus. AreaN/AN/A1972
Mr. Thomas NeidertVP of Global TreasuryN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Corporate governance

QIAGEN N.V.’s ISS governance QualityScore as of 26 September 2021 is 5. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 9; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.